Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events

Global Registry of Acute Coronary Events (GRACE) Investigators; Ph Gabriel Steg; Keith A A Fox; Kim A Eagle; Mark Furman; Frans Van de Werf; Gilles Montalescot; Shaun G Goodman; Alvaro Avezum; Wei Huang; Joel M Gore

doi:10.1093/eurheartj/ehn604

Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events

Global Registry of Acute Coronary Events (GRACE) Investigators, Ph Gabriel Steg, Keith A A Fox, Kim A Eagle, Mark Furman, Frans Van de Werf, Gilles Montalescot, Shaun G Goodman, Alvaro Avezum, Wei Huang, Joel M Gore

Research output: Contribution to journal › Article › peer-review

Abstract

To assess mortality after drug-eluting stent (DES) or bare-metal stent (BMS) for ST-segment elevation myocardial infarction (STEMI).

In this multinational registry, 5093 STEMI patients received a stent: 1313 (26%) a DES and 3780 (74%) only BMS. Groups differed in baseline characteristics, type, or timing of percutaneous coronary intervention, with a higher baseline risk for patients receiving BMS. Two-year follow-up was available in 55 and 60% of the eligible BMS and DES patients, respectively. Unadjusted mortality was lower during hospitalization, similar for the first 6 months after discharge, and higher from 6 months to 2 years, for DES patients compared with that of BMS patients. Overall, unadjusted 2-year mortality was 5.3 vs. 3.9% for BMS vs. DES patients (P = 0.04). In propensity- and risk-adjusted survival analyses (Cox model), post-discharge mortality was not different up to 6 months (P = 0.21) or 1 year (P = 0.34). Late post-discharge mortality was higher in DES patients from 6 months to 2 years (HR 4.90, P = 0.01) or from 1 to 2 years (HR 7.06, P = 0.02). Similar results were observed when factoring in hospital mortality.

The observation of increased late mortality with DES vs. BMS suggests that DES should probably be avoided in STEMI, until more long-term data become available.

Original language	English
Pages (from-to)	321-9
Number of pages	9
Journal	European Heart Journal
Volume	30
Issue number	3
DOIs	https://doi.org/10.1093/eurheartj/ehn604
Publication status	Published - Feb 2009

Access to Document

10.1093/eurheartj/ehn604

Cite this

Global Registry of Acute Coronary Events (GRACE) Investigators, Steg, P. G., Fox, K. A. A., Eagle, K. A., Furman, M., Van de Werf, F., Montalescot, G., Goodman, S. G., Avezum, A., Huang, W., & Gore, J. M. (2009). Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. European Heart Journal, 30(3), 321-9. https://doi.org/10.1093/eurheartj/ehn604

@article{042e304b657d4c0f9a252cdbf79906a3,

title = "Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events",

abstract = "To assess mortality after drug-eluting stent (DES) or bare-metal stent (BMS) for ST-segment elevation myocardial infarction (STEMI).In this multinational registry, 5093 STEMI patients received a stent: 1313 (26%) a DES and 3780 (74%) only BMS. Groups differed in baseline characteristics, type, or timing of percutaneous coronary intervention, with a higher baseline risk for patients receiving BMS. Two-year follow-up was available in 55 and 60% of the eligible BMS and DES patients, respectively. Unadjusted mortality was lower during hospitalization, similar for the first 6 months after discharge, and higher from 6 months to 2 years, for DES patients compared with that of BMS patients. Overall, unadjusted 2-year mortality was 5.3 vs. 3.9% for BMS vs. DES patients (P = 0.04). In propensity- and risk-adjusted survival analyses (Cox model), post-discharge mortality was not different up to 6 months (P = 0.21) or 1 year (P = 0.34). Late post-discharge mortality was higher in DES patients from 6 months to 2 years (HR 4.90, P = 0.01) or from 1 to 2 years (HR 7.06, P = 0.02). Similar results were observed when factoring in hospital mortality.The observation of increased late mortality with DES vs. BMS suggests that DES should probably be avoided in STEMI, until more long-term data become available.",

author = "{Global Registry of Acute Coronary Events (GRACE) Investigators} and Steg, {Ph Gabriel} and Fox, {Keith A A} and Eagle, {Kim A} and Mark Furman and {Van de Werf}, Frans and Gilles Montalescot and Goodman, {Shaun G} and Alvaro Avezum and Wei Huang and Gore, {Joel M}",

year = "2009",

month = feb,

doi = "10.1093/eurheartj/ehn604",

language = "English",

volume = "30",

pages = "321--9",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "3",

}

Global Registry of Acute Coronary Events (GRACE) Investigators, Steg, PG, Fox, KAA, Eagle, KA, Furman, M, Van de Werf, F, Montalescot, G, Goodman, SG, Avezum, A, Huang, W & Gore, JM 2009, 'Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events', European Heart Journal, vol. 30, no. 3, pp. 321-9. https://doi.org/10.1093/eurheartj/ehn604

Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. / Global Registry of Acute Coronary Events (GRACE) Investigators; Steg, Ph Gabriel; Fox, Keith A A et al.

In: European Heart Journal, Vol. 30, No. 3, 02.2009, p. 321-9.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events

AU - Global Registry of Acute Coronary Events (GRACE) Investigators

AU - Steg, Ph Gabriel

AU - Fox, Keith A A

AU - Eagle, Kim A

AU - Furman, Mark

AU - Van de Werf, Frans

AU - Montalescot, Gilles

AU - Goodman, Shaun G

AU - Avezum, Alvaro

AU - Huang, Wei

AU - Gore, Joel M

PY - 2009/2

Y1 - 2009/2

N2 - To assess mortality after drug-eluting stent (DES) or bare-metal stent (BMS) for ST-segment elevation myocardial infarction (STEMI).In this multinational registry, 5093 STEMI patients received a stent: 1313 (26%) a DES and 3780 (74%) only BMS. Groups differed in baseline characteristics, type, or timing of percutaneous coronary intervention, with a higher baseline risk for patients receiving BMS. Two-year follow-up was available in 55 and 60% of the eligible BMS and DES patients, respectively. Unadjusted mortality was lower during hospitalization, similar for the first 6 months after discharge, and higher from 6 months to 2 years, for DES patients compared with that of BMS patients. Overall, unadjusted 2-year mortality was 5.3 vs. 3.9% for BMS vs. DES patients (P = 0.04). In propensity- and risk-adjusted survival analyses (Cox model), post-discharge mortality was not different up to 6 months (P = 0.21) or 1 year (P = 0.34). Late post-discharge mortality was higher in DES patients from 6 months to 2 years (HR 4.90, P = 0.01) or from 1 to 2 years (HR 7.06, P = 0.02). Similar results were observed when factoring in hospital mortality.The observation of increased late mortality with DES vs. BMS suggests that DES should probably be avoided in STEMI, until more long-term data become available.

AB - To assess mortality after drug-eluting stent (DES) or bare-metal stent (BMS) for ST-segment elevation myocardial infarction (STEMI).In this multinational registry, 5093 STEMI patients received a stent: 1313 (26%) a DES and 3780 (74%) only BMS. Groups differed in baseline characteristics, type, or timing of percutaneous coronary intervention, with a higher baseline risk for patients receiving BMS. Two-year follow-up was available in 55 and 60% of the eligible BMS and DES patients, respectively. Unadjusted mortality was lower during hospitalization, similar for the first 6 months after discharge, and higher from 6 months to 2 years, for DES patients compared with that of BMS patients. Overall, unadjusted 2-year mortality was 5.3 vs. 3.9% for BMS vs. DES patients (P = 0.04). In propensity- and risk-adjusted survival analyses (Cox model), post-discharge mortality was not different up to 6 months (P = 0.21) or 1 year (P = 0.34). Late post-discharge mortality was higher in DES patients from 6 months to 2 years (HR 4.90, P = 0.01) or from 1 to 2 years (HR 7.06, P = 0.02). Similar results were observed when factoring in hospital mortality.The observation of increased late mortality with DES vs. BMS suggests that DES should probably be avoided in STEMI, until more long-term data become available.

UR - http://www.scopus.com/inward/record.url?scp=59749103515&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehn604

DO - 10.1093/eurheartj/ehn604

M3 - Article

C2 - 19147604

VL - 30

SP - 321

EP - 329

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 3

ER -

Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events

Abstract

Access to Document

Other files and links

Fingerprint

Cite this